VR
VRCI.LSE Verici Dx Plc
- Market cap
- GBX 15.2M
- P/E
- -
- P/B
- 3.59x
- ROE
- -275.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Jun 2026.
Is VRCI.LSE undervalued?
Graham numberThe Graham number of Verici Dx Plc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Verici Dx Plc fundamental analysis
No fundamental analysis for Verici Dx Plc yet.
Verici Dx Plc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failur…
Full company profileVerici Dx Plc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Verici Dx Plc annual financial statements
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | - | 0.00 | 0.00 | 1.01M | 3.34M | 3.74M | 6.94M |
| Gross Profit | - | - | - | 1.01M | 3.34M | 2.32M | 3.83M |
| Operating Income | -7.00M | -8.33M | -11.5M | -8.87M | -6.11M | -6.93M | -15.7M |
| EBITDA | -2.10M | -7.15M | -10.5M | -7.88M | -5.15M | -6.35M | -14.6M |
| Net Income | -7.10M | -8.33M | -11.4M | -8.73M | -5.87M | -7.08M | -15.8M |
| EPS | -0.08 | -0.06 | -0.07 | -0.05 | -0.03 | -0.01 | -0.01 |
| Balance Sheet | |||||||
| Total Assets | 20.3M | 13.8M | 14.3M | 7.44M | 7.49M | 7.94M | 8.19M |
| Total Liabilities | 682K | 1.80M | 2.80M | 3.89M | 2.23M | 1.44M | 2.45M |
| Shareholders' Equity | 19.6M | 12.0M | 11.5M | 3.56M | 5.27M | 6.51M | 5.75M |
| Cash & Short-term Investments | 17.8M | 10.3M | 9.81M | 2.65M | 4.06M | 3.34M | 2.41M |
| Total Debt | 73.5K | - | 700K | 540K | 371K | 197K | 776K |
| Cash Flow | |||||||
| Operating Cash Flow | -1.28M | -6.34M | -10.1M | -7.16M | -6.02M | -8.39M | -14.9M |
| Capital Expenditure | 38.8K | 966K | 1.31M | 231K | 193K | 2.04K | 54.9K |
| Free Cash Flow | -1.32M | -7.30M | -11.4M | -7.39M | -6.21M | -8.39M | -14.9M |
| Ratios | |||||||
| ROE | -36.2% | -69.5% | -98.7% | -245.5% | -111.6% | -108.8% | -275.3% |
| ROA | -35.0% | -60.4% | -79.4% | -117.3% | -78.4% | -89.1% | -193.0% |
| Net Profit Margin | - | - | - | -862.2% | -175.9% | -189.2% | -227.8% |
| Debt to Equity | 0.00x | - | 0.06x | 0.15x | 0.07x | 0.03x | 0.14x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Verici Dx Plc dividends
Verici Dx Plc has not paid dividends in the last 6 fiscal years.
Who owns Verici Dx Plc
- Insiders 1.43%
- Institutions 45.84%
- Public & others 52.73%
- Shares outstanding 6.66B
- Free float 960M
Verici Dx Plc company profile
- Company name
- Verici Dx Plc
- Ticker
- VRCI.LSE
- ISIN
- GB00BM8HZD43
- Exchange
- London Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 23
- Fiscal year end
- December
- Address
- Avon House, Cardiff, United Kingdom, CF64 2EZ
- Phone
- 44 20 7933 8780
- Website
- vericidx.com
About Verici Dx Plc
Verici Dx plc, together with its subsidiary, Verici Dx Inc, develops prognostic and diagnostic tests for kidney transplant patients in the United Kingdom and the United States. The company develops Tutivia, a post-transplant diagnostic test focused on acute cellular rejection, including sub-clinical rejection; Clarava, a pre-transplant prognosis test for the risk of early acute rejection; and Protega, a liquid biopsy to predict the risk of fibrosis and long-term graft failure. It also offers sequencing services for tumor-only, tumor-normal, and germline exomes; whole transcriptome, targeted RNASeq and ncRNAs; and functional binding multicell assay. In addition, the company provides bioinformatics and data science services for exome analysis options; RNA pipeline; multiomic signature discovery, TCR clonotype antigen identification, custom pipeline building, and predictive modeling; and simulation of drug combinations against multiomic personalized tumor models. It has collaborations with One Lambda Inc. for the commercialization of pre transplant risk assessment (PTRA), a pre-transplant prognosis test for the risk of early acute rejection; The Westmead Institute for Medical Research to determine the factors contributing to graft loss in organ transplants; and FBB Biomed, Inc., which provides research-use-only tests for clinicians seeking insights into neurologic diseases, such as multiple sclerosis and long COVID. Verici Dx plc was incorporated in 2020 and is headquartered in Cardiff, the United Kingdom.
Verici Dx Plc management
3- Ms. Sara jane Barrington A.C.A., A.C.I.M.CEO & Executive Director · born 1967
- Mr. David Mark AndersonCFO & Company Secretary · born 1963
- Keith GilliardSenior Director of Sales